Eiger BioPharmaceuticals Inc (EIGR)

Eiger BioPharmaceuticals Inc Aktie (EIGR) Neueste Nachrichten

Eiger BioPharmaceuticals (EIGR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo New Zealand News

Yahoo New Zealand News

Eiger BioPharmaceuticals (EIGR) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Movies UK

Yahoo Movies UK

Sentynl acquires Eiger's Zokinvy for progeria treatment - Pharmaceutical Technology

Pharmaceutical Technology

StockNews.com Begins Coverage on Eiger BioPharmaceuticals (NASDAQ:EIGR) - Defense World

Defense World

Sentynl Therapeutics, a Zydus company acquires Zokinvy for Progeria from Eiger Biopharma - Medical Dialogues

Medical Dialogues

Biotech Eiger Says Ch. 11 Should Stay In Texas - Law360

Law360

Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of Hutchinson-Gilford ... - PR Newswire

PR Newswire

Eiger Gets Deal With Merck Over $46M Rare-Disease Drug Sale - Law360

Law360

Hutchinson Gilford Progeria Syndrome (HGPS) Therapeutics Market Latest Trends &Innovations | Eiger ... - Amoré

Amoré

Biotech Eiger Can Sell Rare-Disease Drug For $46M In Ch. 11 - Law360

Law360

Eiger Lacks Ties to Texas to File for Bankruptcy There, DOJ Says - Bloomberg Law

Bloomberg Law

Requiem for Eiger Biopharmaceuticals - WSJ - The Wall Street Journal

The Wall Street Journal

Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Why Flora Growth Shares Are Trading Lower By Around 20%; Here Are 20 Stocks Moving Premarket

Benzinga

Biotech Eiger Can Take Sentynl's Improved Drug Bid In Ch. 11 - Law360

Law360

Eiger Files for Bankruptcy, Plans to Shutter Operations After Difficult Year - BioSpace

BioSpace

Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection

GlobeNewswire Inc.

Dow Falls Over 200 Points; ISM Manufacturing PMI Rises In March

Benzinga

Metabolic Diseases-Focused Eiger BioPharmaceuticals Files For Bankruptcy, Stock Nosedives - Benzinga

Benzinga

EIGR Stock Quote Price and Forecast - CNN

CNN

Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and ... - PR Newswire

PR Newswire

Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split - PR Newswire

PR Newswire

Eiger BioPharmaceuticals Insiders US$2.1m Short Of Breakeven On Stock Purchase - Yahoo Finance

Yahoo Finance

Dow Surges 150 Points; US Jobless Claims Decline Sharply

Benzinga

Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update - PR Newswire

PR Newswire

Eiger scraps phase III but delta force deploying in hepatitis - BioWorld Online

BioWorld Online

Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta - PR Newswire

PR Newswire

Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update - PR Newswire

PR Newswire

Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO - PR Newswire

PR Newswire

Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update - PR Newswire

PR Newswire

Eiger BioPharmaceuticals Appoints New Management Team - Contract Pharma

Contract Pharma

Elizabeth Warren, AOC Ask SVB Depositors to Detail Ties to Bank - Bloomberg

Bloomberg

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update - PR Newswire

PR Newswire

Silicon Valley Bank's stranded deposits spread the pain from Tech Valley to Napa Valley - The Economic Times

The Economic Times

Eiger BioPharmaceuticals (EIGR): The Results Are In - The CEO And The CFO Are Out - Seeking Alpha

Seeking Alpha

New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in ... - PR Newswire

PR Newswire

7 Cheap But Risky Biotech Stocks - Barron's

Barron's

Investigation announced for Long-Term Investors in shares of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) - openPR

openPR

EIGR stock plunges after late-stage data for chronic hepatitis candidate (NASDAQ:EIGR) - Seeking Alpha

Seeking Alpha

Eiger BioPharmaceuticals Provides Update on Plans for Emergency Use Authorization Application Following FDA ... - PR Newswire

PR Newswire

Eiger Receives European Approval for Zokinvy® (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and ... - PR Newswire

PR Newswire

Eiger BioPharmaceuticals presents liver study data - Labiotech.eu

Labiotech.eu

Eiger BioPharmaceuticals Announces New Data Supporting Broader Potential of Avexitide in Patients with Post ... - PR Newswire

PR Newswire

Eiger BioPharmaceuticals Enters into $75M Term Loan Agreement and $5M Stock Purchase Agreement with Innovatus ... - PR Newswire

PR Newswire

AnGes and Eiger collaborate to distribute Zokinvy in Japan - Pharmaceutical Technology

Pharmaceutical Technology

Eiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and ... - PR Newswire

PR Newswire

Eiger Announces Publication of Positive Phase 2 Results of Avexitide in Children with Congenital Hyperinsulinism and ... - PR Newswire

PR Newswire

Eiger Appoints New Executive Leadership - Contract Pharma

Contract Pharma

Eiger Biopharmaceuticals Offers Opportunity (NASDAQ:EIGR) - Seeking Alpha

Seeking Alpha

Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a ... - PR Newswire

PR Newswire